In patients with metastatic triple-negative breast cancer, atezolizumab combined with immunogenic, anthracycline-based metronomic chemotherapy improves progression-free survival, including in patients with PD-L1negative disease.
- Andreas Hagen Røssevold
- Nikolai Kragøe Andresen
- Jon Amund Kyte